Intra-Cellular Therapies, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sharon Mates
- Full Time Employees
- 860
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 430 East 29th Street New York City NY United States of America 10016
- IPO Date
- Jan 7, 2014
- CIK
- 0001567514
- Website
- intracellulartherapies.com
- Similar Companies
- Business
- Intra-Cellular Therapies, Inc. (ITCI) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs targeting neuropsychiatric and neurological disorders of the central nervous system. The company offers CAPLYTA (lumateperone), a once-daily oral therapy approved by the U.S. Food and Drug Administration for the treatment of schizophrenia and bipolar depression in adults; it distributes CAPLYTA through third-party wholesale drug distributors to healthcare providers serving patients with these conditions. Its pipeline includes ITI-1284, a Phase II clinical-stage compound under evaluation for generalized anxiety disorder, Alzheimer’s disease-related psychosis and agitation, and other CNS indications; additional investigational programs leverage proprietary intracellular approaches derived from Nobel Prize-winning research by founder Dr. Paul Greengard to address unmet needs in complex psychiatric and neurologic diseases. Founded in 2002 and headquartered in Bedminster, New Jersey, Intra-Cellular Therapies operates primarily in the United States with approximately 860 employees, targeting medical professionals and patients in the healthcare sector. In a major strategic development, Johnson & Johnson completed its $14.6 billion acquisition of Intra-Cellular Therapies in April 2025, integrating it as a business unit within Johnson & Johnson Innovative Medicine to bolster neuroscience leadership; the deal encompasses CAPLYTA, which features a supplemental new drug application accepted by the FDA in February 2025 for adjunctive treatment of major depressive disorder in adults, alongside the broader pipeline.
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
Drugmakers rush to sign deals on first day of industry conference
Intra-Cellular just downgraded at Morgan Stanley, here's why
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?
J&J to buy Intra-Cellular Therapies for $14.6 billion